



COPY OF PAPERS
ORIGINALLY FILED

PATENT
Attorney Docket No. 210485

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ikemoto et al.

Application No. 09/824,447

Art Unit: 1625

Examiner: R. K. Covington

Filed: April 2, 2001

For: CITALOPRAM HYDROBROMIDE
CRYSTAL AND METHOD FOR
CRYSTALLIZATION THEREOF

7
HKD
5-15-02
RECEIVED

MAY 10 2002

RESPONSE TO OFFICE ACTION

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated January 29, 2002, please consider the following remarks.

REMARKS

The Present Invention

The present invention pertains to citalopram hydrobromide with specific crystal properties and a method of crystallizing citalopram hydrobromide.

The Pending Claims

Claims 1-19 are currently pending. Reconsideration of the pending claims is respectfully requested.

Summary of the Office Action

The Office Action rejects claims 1-8 under 35 U.S.C. § 103(a) as unpatentable for obviousness over U.S. Patent 4,136'193 (Bogeso et al. - Kefalas) (US '193) in combination with U.K. Patent Application 2,357'762 (Peterson et al. - Lundbeck) (UK '762). The Office Action also rejects claims 1-19 under 35 U.S.C. § 103(a) as unpatentable for obviousness over U.K. Patent Application 2,357'762 (Peterson et al. - Lundbeck) (UK '762) in view of Ram (Chemical Abstract 113:231122).